Merck: EU approves Keytruda immunotherapy for kidney cancer
(CercleFinance.com) - Merck's immunotherapy drug Keytruda has been approved in Europe for patients with the most common type of kidney cancer, the US drugmaker said on Wednesday.
The European approval is for patients with advanced renal cell carcinoma, one of the most lethal types of cancer, with the majority of patients dying within five years after their initial diagnosis.
About 90% kidney cancers are renal cell carcinomas.
It is estimated that 136,500 new cases of kidney cancer were diagnosed in Europe last year, with approximately 54,700 people dying from the disease.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The European approval is for patients with advanced renal cell carcinoma, one of the most lethal types of cancer, with the majority of patients dying within five years after their initial diagnosis.
About 90% kidney cancers are renal cell carcinomas.
It is estimated that 136,500 new cases of kidney cancer were diagnosed in Europe last year, with approximately 54,700 people dying from the disease.
Copyright (c) 2019 CercleFinance.com. All rights reserved.